MDR: extra time will not rescue a portfolio without decisions

When the Medical Devices Regulation was adopted in 2017, manufacturers appeared to have several years to adapt. Its application was later deferred, selected transition periods were extended to 2027 or 2028, and new digital deadlines followed. That shifting timetable can create a false sense of breathing room. A device does not qualify for a transition automatically: its class, certificate, unchanged design and intended purpose, quality system and relationship with a notified body all matter. This reading turns the timetable into portfolio decisions. It explains how to separate devices to continue, remediate, transfer or discontinue; why clinical evidence and regulatory capacity must be assessed together; and what a partner can sell as an initial diagnostic without promising certification. For getfishnet, the opportunity is not fear built around a deadline. It is finding manufacturers whose product decisions, notified-body constraints or Swiss–EU market access needs make a focused review worth buying now. General analysis updated on 7 August 2026. It is not a conformity assessment, individual regulatory advice, or a decision by a notified body or authority.

MDR adoption replaced the previous European framework with stronger requirements for classification, evidence, quality systems, post-market surveillance and traceability. For a Swiss manufacturer targeting the European Union or relying on Switzerland's recognition of CE marking, the change affects the device's entire life cycle, not just its certificate.

Regulation (EU) 2017/745 was adopted on 5 April 2017 and has applied since 26 May 2021, following a one-year deferral. Swissmedic notes that Switzerland relies on conformity assessment and, under the applicable framework, unilaterally recognises CE marking for access to its market. Manufacturers must still meet the Swiss obligations governing economic operators and registration.

The MDR demands greater discipline in clinical evidence, risk management, surveillance and accountability. A legacy product family may move to a different class or require a notified body. The portfolio therefore needs to be reviewed device by device, including variants, intended purposes and target markets.

A portfolio review is the most useful first purchase: one record per device, showing transition status, major gaps, dependencies and the next decision. It supports management choices and work with the appropriate specialists without issuing a certificate.

The 2027 and 2028 deadlines are not an automatic reprieve because Regulation (EU) 2023/607 sets conditions for legacy devices. Among other requirements, they must remain compliant with the previous rules, undergo no significant change, and complete the prescribed transition steps. The applicable end date depends on the device class and type.

The European regulation sets 31 December 2027 for selected class III and class IIb implantable devices. It sets 31 December 2028 for other class IIb devices, class IIa devices, and selected class I sterile devices or devices with a measuring function. Devices that now require a notified body under the MDR may also qualify for the 2028 date, subject to the conditions.

These are deadlines for placing devices on the market or putting them into service under the applicable transition, not blanket permission to wait. A significant change to the design or intended purpose can alter the analysis. The manufacturer must retain compliance with the previous law and meet every relevant transition condition.

The initial diagnostic is a map of twenty to fifty devices or product families, organised by deadline, evidence, capacity and economic value. It exposes urgent decisions and unknowns. The assignment has a defined output and can be charged before a longer transition programme, without promising that any submission will be accepted.

Start with the commercial product list, then reconcile it against certificates, declarations, intended purposes, technical documentation and countries of sale. Give every row an owner and a next decision: continue, remediate, transfer, suspend or withdraw. Product families must not conceal a variant with a different purpose or class.

The partner prices the review according to the number of devices, data quality and markets involved. Competence, availability, insurance, secure access and pricing must all be confirmed before acquisition begins. Where specialist advice is missing, record the uncertainty and escalate the case.

Prioritisation weighs the device's value, the feasibility of its evidence, transition cost, notified-body capacity and the importance of the market. It does not rank products on revenue alone. A device that is essential to a range or customer may justify investment despite limited direct volume.

Management builds scenarios. Continuing reserves resources and commits to a timetable. Transferring requires a compatible organisation and documentation. Modifying the product may improve it but remove a transition route. Discontinuing requires a plan for customers, surveillance duties and stock.

How to read the diagram. Value and feasibility are considered together. Withdrawal becomes a managed decision rather than a quiet abandonment.

This approach also stops teams from pursuing everything by default. A fragmented portfolio can consume clinical and quality capacity that strategic devices need. Governance should always show which product receives the next hour of expert time, and why.

Notified-body capacity becomes a product variable because complete documentation is not enough if the assessment cannot be scheduled. Manufacturers must check designation scope, availability, contractual milestones and lead times. This dependency belongs in the portfolio decision alongside evidence and budget.

The European extension was intended in part to reduce shortage risks caused by bottlenecks. It did not remove capacity limits. A late application, unsuitable scope or incomplete file can shift the timetable. Where the transition depends on them, the review must retain the formal application, written agreement and related correspondence.

A partner must not sell privileged access to a notified body. The legitimate service is to prepare the portfolio, evidence and decisions so that the engagement can proceed. Any promise of a place, timetable or certification stays outside the commercial message.

In 2026, manufacturers must connect MDR status with Swiss operator and registration duties. Swissmedic made device registration in swissdamed mandatory from 1 July 2026, with a general transition until 31 December 2026 and no grace period in selected cases. This digital deadline does not replace any conformity requirement.

Swissmedic states that registration covers devices under current law and selected legacy devices that remain on the market. Serious incidents, field safety corrective actions and trend reports can trigger an immediate registration requirement. The manufacturer, authorised representative and importer roles must be kept distinct and linked to the device data.

A portfolio review can therefore lead to a separate, focused purchase: preparing swissdamed data and responsibilities. This must not be confused with MDR certification. A registered data record does not establish conformity; it makes device identification and surveillance more structured.

A credible pool includes Swiss manufacturers with legacy devices, companies changing notified bodies, introducing variants, entering new markets or preparing for swissdamed. Public signals help prioritise accounts but prove neither delay nor non-compliance. Acquisition targets professional decision-makers, never patients.

A new product, regulatory hire, portfolio acquisition, change of intended purpose, supply disruption or partner change can create a decision point. The message offers a bounded mapping exercise without dramatising the date or assuming the condition of the file.

The Swiss medtech market page connects this reading with Swiss obligations, in vitro diagnostics and historical derogations. Content answers existing questions, professional networks build trust, and direct contact follows a verified event. Neither portfolio value nor target-market value is counted as revenue generated by getfishnet.

Management reporting should reduce each device to a few controllable decisions: status, deadline, critical gap, owner, dependency and next action. Detailed evidence remains in the source files. The management view allocates capacity and escalates blockers; it does not replace the quality system.

A short committee reviews changes, blockers and decisions without opening every technical file. Meetings become more frequent near deadlines or when a significant change is proposed. Each decision retains its rationale and approver.

Mapping creates legitimate recurring work when the portfolio changes through a new variant, clinical evidence, certificate, surveillance signal, market or deadline. Quarterly or event-driven reviews can keep decisions current. Each cycle must produce an identifiable decision, not an automatic document subscription.

After the initial assignment, a partner may support a priority batch, prepare a management review or check registration data. Each service retains its own scope and price. Recurring revenue is recognised only after a new assignment has been invoiced and paid.

Commercial measures should cover paid diagnostics, decision speed, margin and resulting assignments. Meetings, replies and downloads are not revenue. Confidential outcomes remain confidential, and no fictional example is presented as an observed campaign.

The campaign must exclude promises of certification, notified-body timing or guaranteed market access. The partner must confirm competence, insurance, capacity, confidentiality and the boundaries between its role and the authority's. If the device status or responsibility cannot be qualified, the case must be declined or escalated.

The relevant authority sources are Swissmedic, the European Commission, EUR-Lex, Regulation (EU) 2017/745 and its amendments, and the Swiss ordinances. They establish dates and conditions. They do not publish consultancy prices, certification probabilities or an accessible volume of assignments.

The complimentary eligibility test reviews your speciality, manufacturer pool, initial diagnostic and delivery capacity. It does not qualify any device. Its purpose is to decide whether getfishnet and your team can build a tailored strategy around real portfolio decisions, with clear responsibilities and limits.